Phase 2 study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) therapy for refractory/relapsed malignant lymphoma.

Phase 2 study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) therapy for refractory/relapsed malignant lymphoma. - Phase 2 study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) therapy for refractory/relapsed malignant lymphoma.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011682

Enrollment

Registered

2013-09-09

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant lymphoma

Interventions

Investigation for efficacy and safety of GDP therapy for refractory/relapsed malignant lymphoma.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Pathohistological diagnosed for malignant lymphoma 2 Relapsed/refractory disease 3 Patients approved by written informed consent with age:18-70 4 Performance status of 0-2 5 No major organ dysfunction

Exclusion criteria

Exclusion criteria: 1 Neutrophils <1000/mm3 2 Platelet <75,000/mm3 3 Cre >1.5mg/dL 4 AST or ALT > 5xULN, T.Bil >2.0mg/dL 5 Angina pectoris, myocardial infarction, treatment required arrhythmia 6 Interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema 7 Patients with CNS invasion of lymphoma cells 8 Radiation therapy for thorax 9 Severe bacterial infection

Design outcomes

Primary

Measure	Time frame
Overall response rate	—

Secondary

Measure	Time frame
Progression free survival Overall complete response rate Adverse effect rate	—

Countries

Japan

Contacts

Public ContactYoshihiro Kameoka

Akita University School of Medicine Dept. of hematology

ykameoka@doc.med.akita-u.ac.jp018-834-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026